| Vries, Elisabeth GE de |
| Active, not recruiting | 2 | 81 | Europe | MPDL3280A | University Medical Center Groningen | Locally Advanced or Metastatic Solid Tumors | 09/23 | 07/24 | | |
| Not yet recruiting | 2 | 30 | Europe | 89Zr-Df-crefmirlimab PET scan, Nivolumab, Cetrelimab, zirconium Zr 89 crefmirlimab berdoxam, Zr-89 crefmirlimab berdoxam, 89Zr-Df-crefmirlimab, 89Zr-Df-IAB22M2C | University Medical Center Groningen | Locally Advanced Solid Tumor | 11/28 | 11/28 | | |
| Active, not recruiting | 1 | 5 | Europe | Radiolabelled CB307, 89Zr-CB307, CB307 | Crescendo Biologics Ltd., University Medical Center Groningen | Advanced and/or Metastatic Solid Tumours | 01/24 | 10/24 | | |
| Recruiting | 1 | 70 | Europe, US | CB307 | Crescendo Biologics Ltd. | Advanced and/or Metastatic Solid Tumours | 07/24 | 09/24 | | |
| Active, not recruiting | N/A | 45 | Europe | 89Zr-MPDL-3280A-PET scans | University Medical Center Groningen | Locally Advanced or Metastatic Solid Tumors Irrespective of PD-L1 Expression | 11/20 | 06/24 | | |
| Withdrawn | N/A | 20 | Europe | 89Zr-atezolizumab PET scans | University Medical Center Groningen, Amsterdam UMC, location VUmc, Stichting Hemato-Oncologie voor Volwassenen Nederland, Hoffmann-La Roche | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | 05/22 | 05/22 | | |
| Soo, Ross |
NCT05305131: Phase II Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer |
|
|
| Not yet recruiting | 2 | 50 | RoW | cisplatin and gemcitabine, induction chemotherapy cisplatin, gemcitabine, bevacizumab and pembrolizumab. | National University Hospital, Singapore | Nasopharyngeal Cancer | 03/25 | 03/26 | | |
| Terminated | 2 | 6 | Europe, RoW | Osimertinib, Tagrisso, Stereotactic Body Radiation Therapy (SBRT) | ETOP IBCSG Partners Foundation, AstraZeneca | NSCLC Stage IV, EGFR Gene Mutation | 10/23 | 02/24 | | |
| Recruiting | 2 | 60 | Europe | Amivantamab, Lazertinib, Zirabev | ETOP IBCSG Partners Foundation, Janssen Pharmaceuticals | Non Small Cell Lung Cancer | 03/26 | 09/26 | | |
NCT06062823: Study of EGFR TKI in Patients With Advanced NSCLC Harbouring EGFR Mutations |
|
|
| Recruiting | 2 | 35 | RoW | Afatinib 40 MG, Gilotrif | National University Hospital, Singapore | NSCLC | 10/26 | 12/26 | | |
| Active, not recruiting | 1/2 | 284 | Europe, Japan, US, RoW | CLN-081, TAS6417; zipalertinib | Cullinan Therapeutics Inc. | Non Small Cell Lung Cancer, EGFR Exon 20 Mutation | 12/24 | 12/24 | | |
|
| Recruiting | 1/2 | 359 | Europe, Canada, Japan, US, RoW | NVL-520 | Nuvalent Inc., Nuvalent, Inc. | Locally Advanced Solid Tumor, Metastatic Solid Tumor | 10/25 | 10/26 | | |
| Recruiting | 1/2 | 470 | Europe, Canada, Japan, US, RoW | NVL-655 | Nuvalent Inc., Nuvalent, Inc. | Locally Advanced Solid Tumor, Metastatic Solid Tumor | 02/26 | 03/26 | | |
NCT05381038: Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI |
|
|
| Not yet recruiting | 1/2 | 10 | RoW | QPOP, CURATE.AI, Azacitidine + docetaxel, Azacitidine + paclitaxel, Azacitidine + irinotecan | National University Hospital, Singapore, The N.1 Institute for Health (N.1), Cancer Science Institute of Singapore | Solid Tumor, Gastrointestinal Cancer, Breast Cancer | 10/26 | 04/27 | | |
| Recruiting | 1/2 | 500 | Europe, Canada, Japan, US, RoW | Oral repotrectinib (TPX-0005), repotrectinib | Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd. | Locally Advanced Solid Tumors, Metastatic Solid Tumors | 02/28 | 02/28 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Recruiting | N/A | 69 | RoW | Afatinib, Giotrif | National University Hospital, Singapore, Boehringer Ingelheim | Non-Small Cell Lung Cancer, Epidermal Growth Factor Receptor Mutation | 05/25 | 12/25 | | |
| Brouwers, Adrienne H |
NCT05463913: Lung Nodule Detection Using Ultra-long FOV PET/CT |
|
|
| Recruiting | 4 | 20 | Europe | 18F-FDG, PET/CT imaging | University Medical Center Groningen | Lung Cancer | 12/23 | 12/23 | | |
MIMETIC, NCT05534594: Evaluation of the 18F-PSMA Positron Emission Tomography (PET)/CT in Patients With Medullary Thyroid Cancer |
|
|
| Recruiting | N/A | 15 | Europe | 18F-PSMA-1007, Fluorine-18 labeled prostate specific membrane antigen | University Medical Center Groningen | Medullary Thyroid Cancer, Medullary Thyroid Carcinoma, Thyroid Carcinoma, Medullary, Thyroid Cancer, Medullary | 09/24 | 12/24 | | |
| Gietema, JA |
| Recruiting | N/A | 48 | Europe | Anthracyclines, Trastuzumab, Cisplatin, Bleomycin | University Medical Center Groningen | Toxicity Due to Chemotherapy, Cardiovascular Morbidity, Cancer, Treatment-Related | 01/25 | 01/25 | | |
| Completed | N/A | 101 | Europe | | University Medical Center Groningen | Testicular Cancer | 04/24 | 04/24 | | |
| Active, not recruiting | N/A | 163 | Europe | | University Medical Center Groningen | Testicular Cancer | 01/25 | 01/25 | | |
| Slebos, Dirk-Jan |
EFFORT, NCT04520152: Evaluation of the Free Flow Medical Lung Tensioning Device System for the Treatment of Severe Emphysema |
|
|
| Completed | N/A | 14 | Europe | FreeFlowMedical Lung Tensioning Device | University Medical Center Groningen | Emphysema or COPD | 11/23 | 11/23 | | |
SOLVE, NCT03474471: A Trial on the Effects of Bronchoscopic Lung Volume Reduction in Severe Emphysema. |
|
|
| Completed | N/A | 96 | Europe | Pulmonary rehabilitation, EBV treatment | University Medical Center Groningen, Maastricht University Medical Center, Center of Expertise for Chronic Organ Failure | Emphysema | 04/23 | 04/23 | | |
| Completed | N/A | 102 | Europe, RoW | AeriSeal, Zephyr Valves, Bronchoscopic Lung Volume Reduction (BLVR), Zephyr System | Pulmonx Corporation | Emphysema, COPD, Severe Emphysema | 10/23 | 10/24 | | |
NCT06035120: An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients with Severe Emphysema |
|
|
| Recruiting | N/A | 200 | Europe, US, RoW | AeriSeal System | Pulmonx Corporation | Emphysema, Pulmonary, Emphysema or COPD | 06/27 | 03/28 | | |
| Completed | N/A | 25 | Europe | Echography | University Medical Center Groningen | Emphysema | 02/24 | 02/24 | | |
IAB-1, NCT05087641: A Multicenter, Prospective Trial of the IAB in Adults Suffering From COPD/Emphysema |
|
|
| Active, not recruiting | N/A | 20 | Europe, RoW | IAB System | Pulmair Medical, Inc. | Emphysema, Pulmonary Disease, Chronic Obstructive | 04/24 | 01/27 | | |
| Recruiting | N/A | 150 | Europe | tissue and blood sampling | University Medical Center Groningen | Emphysema or COPD | 03/27 | 03/27 | | |
RheSolve, NCT04677465: Clinical Study of the RheOx Bronchial Rheoplasty System in Treating the Symptoms of Chronic Bronchitis |
|
|
| Active, not recruiting | N/A | 270 | Europe, US | RheOx Bronchial Rheoplasty, Sham Procedure | Gala Therapeutics, Inc. | Chronic Bronchitis | 05/24 | 10/25 | | |
| Active, not recruiting | N/A | 464 | Europe, US | Targeted Lung Denervation (TLD), TLD, TLD Therapy, Optimal Medical Care | Nuvaira, Inc. | COPD | 10/24 | 09/28 | | |
NCT06655428: The REDUCE EU Study - Endobronchial Thermal Liquid Ablation (ETLA) for the Treatment of Emphysema |
|
|
| Recruiting | N/A | 30 | Europe | Endobronchial Therman Liquid Ablation (ETLA), Bronchoscopic lung volume reduction | Morair Medtech, LLC | Emphysema or COPD, Emphysema, Emphysema, Pulmonary, COPD, COPD (Chronic Obstructive Pulmonary Disease) | 02/26 | 05/26 | | |
BREATHE-2, NCT05949645: Study to Assess Safety, Feasibility, and Preliminary Efficacy of the Apreo Implant for Severe Emphysema |
|
|
| Active, not recruiting | N/A | 30 | Europe | Apreo Implant Group | Apreo Health, Inc. | Emphysema or COPD | 10/24 | 06/26 | | |
ENDURANCE, NCT06025500: Analysing Peripheral Skeletal Muscle Function Before and After Endobronchial Valve Treatment |
|
|
| Recruiting | N/A | 15 | Europe | 31P-Magnetic Resonance Spectroscopy (31P-MRS), Muscle biopsy | University Medical Center Groningen | Emphysema | 12/25 | 12/25 | | |
| Recruiting | N/A | 500 | Europe | | University Medical Center Groningen | COPD | 01/28 | 01/28 | | |
NAVIGATOR, NCT05383105: Virtual Bronchoscopic Navigation to Increase Diagnostic Yield in Patients With Pulmonary Nodules |
|
|
| Recruiting | N/A | 100 | Europe | Virtual bronchoscopic navigation, Archimedes | University Medical Center Groningen | Pulmonary Nodules, Solitary | 05/26 | 05/26 | | |
| Huls, Gerwin G |
| Active, not recruiting | 3 | 606 | Europe, RoW | standard combination chemotherapy, "3+7" induction chemotherapy, Intensive combined chemotherapy, decitabine, Dacogen | European Organisation for Research and Treatment of Cancer - EORTC, Janssen Pharmaceuticals, Gruppo Italiano Malattie EMatologiche dell'Adulto | Acute Myeloid Leukemia (AML) | 03/22 | 12/23 | | |
NCT06652438: Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML |
|
|
| Not yet recruiting | 3 | 415 | Europe | Revumenib, Placebo | Stichting Hemato-Oncologie voor Volwassenen Nederland, German-Austrian Acute Myeloid Leukemia Study Group, United Kingdom AML Research Network | Acute Myeloid Leukemia, Adult | 05/28 | 05/31 | | |
| Active, not recruiting | 2 | 140 | Europe | Decitabine, Dacogen, Midostaurin, Rydapt | Stichting Hemato-Oncologie voor Volwassenen Nederland, Swiss Group for Clinical Cancer Research | AML/MDS | 11/21 | 11/26 | | |
| Completed | 2 | 88 | Europe | Anakinra, Kineret, Placebos | Radboud University Medical Center, University Medical Center Groningen, Dutch Cancer Society | Multiple Myeloma | 03/23 | 02/24 | | |
NCT05949125: Dose-escalating Trial With Allo-RevCAR01-T Cells in Combination With CD123 Target Module (R-TM123) for Participants With Selected Hematologic Malignancies Positive for CD123 |
|
|
| Recruiting | 1 | 37 | Europe | Cyclophosphamide (Non-IMP, Lymphodepletion), Fludarabine (Non-IMP, Lymphodepletion), R-TM123, R-TM123 is one component of the Allo-RevCAR01-T-CD123 treatment, Allo-RevCAR01-T, Allo-RevCAR01-T is one component of the Allo-RevCAR01-T-CD123 treatment | AvenCell Europe GmbH, Allucent (NL) BV | Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | 12/25 | 06/26 | | |
| Vellenga |
| Recruiting | N/A | 300 | Europe | WES, Several assays, Hemostasis (several screening tests, several diagnostic tests, global assay), Fibrinolysis, Lupus anticoagulans, Anti β2 glycoprotein | Radboud University Medical Center, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Academisch Ziekenhuis Maastricht, Erasmus Medical Center, Maxima Medical Center, Academisch Ziekenhuis Groningen, UMC Utrecht, Leiden University Medical Center, Haga Hospital | Rare Bleeding Disorders | 07/21 | 01/22 | | |
| Jänisch, Thomas |
| Active, not recruiting | N/A | 8894 | Europe, RoW | COVID-19 vaccination | University of Bologna, Universita di Verona, Hospital Universitario Virgen Macarena, Azienda Ospedaliera di Padova, Azienda Ospedaliero-Universitaria di Parma, Azienda Ulss 2 Marca Trevigiana, University College Dublin, Luxembourg Institute of Health, ICONA Foundation, University Medical Center Groningen, University of Buenos Aires, PENTA Foundation, Universiteit Antwerpen, Institut National de la Santé Et de la Recherche Médicale, France, Helmholtz Zentrum München, CINECA consorzio universitario italiano, Charite University, Berlin, Germany, Centre de Recherche Médicale de Lambaréné | SARS CoV 2 Infection, Vaccination; Infection, Breakthrough Infection | 07/23 | 11/24 | | |
| Berger, Marjolein Y |
| Recruiting | N/A | 38 | Europe | Lifestyle InterVEntion (LIVE) | University Medical Center Groningen, GGZ Drenthe Mental Health Institution | Cardiovascular Risk, Depression, Unipolar, Depression, Bipolar | 12/25 | 12/25 | | |
ZelfHy, NCT05636358: Hypnotherapy Through Self-exercises in Children With Functional Abdominal Pain in Primary Care |
|
|
| Completed | N/A | 152 | Europe | Home-based hypnotherapy | University Medical Center Groningen, ZonMw: The Netherlands Organisation for Health Research and Development | Functional Gastrointestinal Disorders, Irritable Bowel Syndrome, Functional Abdominal Pain Syndrome | 12/24 | 12/24 | | |
| Recruiting | N/A | 455 | Europe | Echocardiography | University Medical Center Groningen, ZonMw: The Netherlands Organisation for Health Research and Development | Neoplasm, Breast, Heart Failure, Cardiotoxicity, Ventricular Dysfunction | 12/25 | 12/26 | | |
| Plukker, John Th |
NCT03283527: Organoid Based Response Prediction in Esophageal Cancer |
|
|
| Recruiting | N/A | 100 | Europe | | University Medical Center Groningen | Organoid, Esophageal Cancer, Chemoradiation | 12/23 | 12/23 | | |
| Dam, Gooitzen van |
| Recruiting | 2 | 600 | Europe | AKS-452X | University Medical Center Groningen, TRACER Europe BV, PRA Health Sciences | COVID-19 | 07/22 | 02/23 | | |
| Recruiting | 1 | 32 | Europe | 89Zr-DFO-N-Suc-F8scFv, 89Zr-DFO-N-Suc-C9scFv, PET/CT scan | Var2 Pharmaceuticals, TRACER Europe BV | Solid Tumor, Colon Carcinoma, Rectal Carcinoma, Osteosarcoma, Chondrosarcoma, Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, Esophageal Carcinoma, Gastric Carcinoma, Pancreas Carcinoma, Bladder Carcinoma, Glioblastoma | 01/26 | 01/26 | | |
| Nagengast, W B |
| Recruiting | 2 | 60 | Europe | Bevacizumab-IRDye800CW, Fluorescence endoscopy | University Medical Center Groningen, Helmholtz Zentrum München | Barrett Esophagus | 09/21 | 10/21 | | |
| Recruiting | 1/2 | 12 | Europe | Bevacizumab-IRDye800CW, Tracer administration, near infrared (NIR) fluorescence imaging, optical imaging | University Medical Center Groningen | Hilar Cholangiocarcinoma | 12/21 | 12/21 | | |
VISION, NCT04112212: Using Vedolizumab-800CW to Gain Insight Into Local Drug Distribution and Mucosal Target Cells in IBD Patients |
|
|
| Completed | 1 | 38 | Europe | Fluorescence molecular imaging procedure using vedolizumab-800CW, Fluorescence molecular imaging procedure without prior administration of vedolizumab-800CW, Control group, Fluorescence molecular imaging procedure using vedolizumab-800CW with prior administration of unlabeled vedolizumab | University Medical Center Groningen | Crohn Disease, Colitis, Ulcerative | 10/22 | 01/23 | | |
| Completed | 1 | 12 | Europe | Bevacizumab-IRDye800CW | University Medical Center Groningen | Age-Related Macular Degeneration, NAMD | 03/23 | 03/24 | | |
| Not yet recruiting | 1 | 30 | Europe | Adalimumab-800CW, Humira, Fluorescence Imaging | University Medical Center Groningen, AbbVie | IBD, Rheumatoid Arthritis | 06/24 | 12/24 | | |
SENSITIVE, NCT05247346: Early Detection of Cancer Onset Based on Sensing Field Cancerization at the Organ Level in the Alimentary Tract Using an Integrated Stimulated Raman/Scattering Modality for Endoscopic Real-time in Vivo Measurements |
|
|
| Recruiting | N/A | 60 | Europe | SENSITIVE system | University Medical Center Groningen, Technical University of Munich, Universidad Carlos III de Madrid, Biomedical Research Foundation of the Academy of Athens | Esophageal Adenocarcinoma, Barrett Esophagus, Colorectal Adenoma, Colorectal Polyp, Colorectal Neoplasms, Colorectal Adenocarcinoma, Carcinogenesis | 12/23 | 12/24 | | |
NCT03222635: Prospective Endoscopic Follow-up of Patients With Submucosal and High Risk Mucosal Esophageal Adenocarcinoma |
|
|
| Recruiting | N/A | 225 | Europe, RoW | Endoscopic follow-up | Amsterdam UMC | Submucosal Esophageal Adenocarcinoma, Barrett Esophagus, High-risk Mucosal Esophageal Adenocarcinoma | 07/28 | 07/28 | | |
| Hartman, Jorine |
| Completed | N/A | 102 | Europe, RoW | AeriSeal, Zephyr Valves, Bronchoscopic Lung Volume Reduction (BLVR), Zephyr System | Pulmonx Corporation | Emphysema, COPD, Severe Emphysema | 10/23 | 10/24 | | |
RheSolve, NCT04677465: Clinical Study of the RheOx Bronchial Rheoplasty System in Treating the Symptoms of Chronic Bronchitis |
|
|
| Active, not recruiting | N/A | 270 | Europe, US | RheOx Bronchial Rheoplasty, Sham Procedure | Gala Therapeutics, Inc. | Chronic Bronchitis | 05/24 | 10/25 | | |
| Active, not recruiting | N/A | 464 | Europe, US | Targeted Lung Denervation (TLD), TLD, TLD Therapy, Optimal Medical Care | Nuvaira, Inc. | COPD | 10/24 | 09/28 | | |
| Recruiting | N/A | 25 | Europe | PEP-buddy | University Medical Center Groningen | COPD | 12/24 | 12/24 | | |
| Not yet recruiting | N/A | 20 | Europe | Endobronchial valve treatment | Dirk-Jan Slebos | COPD | 08/26 | 08/26 | | |
ENDURANCE, NCT06025500: Analysing Peripheral Skeletal Muscle Function Before and After Endobronchial Valve Treatment |
|
|
| Recruiting | N/A | 15 | Europe | 31P-Magnetic Resonance Spectroscopy (31P-MRS), Muscle biopsy | University Medical Center Groningen | Emphysema | 12/25 | 12/25 | | |
| Ares, Luis Paz |
COSTAR Lung, NCT04655976 / 2020-003433-37: Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy |
|
|
| Active, not recruiting | 3 | 758 | Europe, Canada, Japan, US, RoW | Cobolimab, Dostarlimab, Docetaxel | GlaxoSmithKline | Lung Cancer, Non-Small Cell | 04/25 | 10/25 | | |
NCT03496766: Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS |
|
|
| Terminated | 2 | 9 | Europe | Tipifarnib, Zarnestra | Spanish Lung Cancer Group | Non Small Cell Lung Cancer | 10/22 | 11/22 | | |
| Recruiting | 2 | 340 | Europe, Japan, US, RoW | Pembrolizumab, Dostarlimab, GSK4057190, Belrestotug, EOS884448, GSK4428859A, Nelistotug, GSK6097608 | GlaxoSmithKline, iTeos Therapeutics | Lung Cancer, Non-Small Cell | 10/25 | 10/28 | | |
| Recruiting | 1/2 | 470 | Europe, Canada, Japan, US, RoW | NVL-655 | Nuvalent Inc., Nuvalent, Inc. | Locally Advanced Solid Tumor, Metastatic Solid Tumor | 02/26 | 03/26 | | |
NCT06322693: A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) |
|
|
| Recruiting | 1 | 475 | Europe, US, RoW | TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin | GlaxoSmithKline | Neoplasms | 08/25 | 02/27 | | |
| Recruiting | 1 | 447 | Europe, US, RoW | TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin | Tesaro, Inc. | Neoplasms | 04/25 | 04/27 | | |
|
|
|
| Langendijk, J Hans A |
PRIDE, NCT03474341: Preoperative Image-guided Identification of Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer |
|
|
| Recruiting | N/A | 200 | Europe | MRI, Magnetic Resonance Imaging, DW-MRI, DCE-MRI, T2W, PET-CT, 18-F FDG PET-CT, PET, Endoscopy, Endoscopic assessment, EUS, Blood samples, ctDNA | UMC Utrecht, University Medical Center Groningen, The Netherlands Cancer Institute, Koningin Wilhelmina Fonds, Amsterdam UMC, location VUmc | Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms | 09/21 | 01/22 | | |
| Recruiting | N/A | 2000 | Europe | retrospective | University Medical Center Groningen, Dutch Cancer Society, Comprehensive Cancer Centre The Netherlands, Dutch Institute for Clinical Auditing (DICA), ZorgTTP | The Aim of This Project is to Develop and Validate NTCP-models for Complications After nCRT (and Surgical Resection) | 06/25 | 06/30 | | |
| Jansen, Nicolaas Koos JG |
CRUCIAL, NCT04217421 / 2017-004596-31: Cerebrum and Cardiac Protection With Allopurinol in Neonates With Critical Congenital Heart Disease Requiring Cardiac Surgery With Cardiopulmonary Bypass |
|
|
| Recruiting | 3 | 236 | Europe | Allopurinol, Mannitol | dr. M.J.N.L. Benders, ZonMw: The Netherlands Organisation for Health Research and Development, University Medical Center Groningen, Erasmus Medical Center, University Medical Center Nijmegen, ACE Pharmaceuticals BV | Congenital Heart Disease in Children, Neuroprotection | 10/26 | 12/28 | | |
| Bos, Arend F |
CRUCIAL, NCT04217421 / 2017-004596-31: Cerebrum and Cardiac Protection With Allopurinol in Neonates With Critical Congenital Heart Disease Requiring Cardiac Surgery With Cardiopulmonary Bypass |
|
|
| Recruiting | 3 | 236 | Europe | Allopurinol, Mannitol | dr. M.J.N.L. Benders, ZonMw: The Netherlands Organisation for Health Research and Development, University Medical Center Groningen, Erasmus Medical Center, University Medical Center Nijmegen, ACE Pharmaceuticals BV | Congenital Heart Disease in Children, Neuroprotection | 10/26 | 12/28 | | |
| Calles, Antonio |
| Active, not recruiting | 2 | 68 | Europe, RoW | Lorlatinib | European Organisation for Research and Treatment of Cancer - EORTC, European Organisation for the Research and Treatment of Cancer, Pfizer NV/SA, European Organization for the Research and Treatment of Cancer (EORTC) | Non Small Cell Lung Cancer | 07/24 | 11/24 | | |
| Active, not recruiting | 1/2 | 28 | Europe | Lurbinectedin, PM01183, Zepsyre, Pembrolizumab, Keytruda | Antonio Calles Blanco, MedSIR, PharmaMar, Merck Sharp & Dohme LLC | Small Cell Lung Carcinoma | 09/23 | 03/25 | | |
RAMP 203, NCT05074810: Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients |
|
|
| Recruiting | 1/2 | 153 | Europe, US | avutometinib and sotorasib, AMG 510, LUMAKRAS™, VS-6766, avutometinib and sotorasib and defactinib, VS-6063 | Verastem, Inc., Amgen | Non Small Cell Lung Cancer, KRAS Activating Mutation | 09/25 | 04/27 | | |
METex14, NCT04868877 / 2021-000203-20: Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination |
|
|
| Recruiting | 1/2 | 576 | Europe, US, RoW | MCLA-129, bispecific, Osimertinib, Tagrisso, Chemotherapy | Merus N.V. | Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer | 03/26 | 03/27 | | |
| Recruiting | 1/2 | 359 | Europe, Canada, Japan, US, RoW | NVL-520 | Nuvalent Inc., Nuvalent, Inc. | Locally Advanced Solid Tumor, Metastatic Solid Tumor | 10/25 | 10/26 | | |
| Recruiting | 1/2 | 470 | Europe, Canada, Japan, US, RoW | NVL-655 | Nuvalent Inc., Nuvalent, Inc. | Locally Advanced Solid Tumor, Metastatic Solid Tumor | 02/26 | 03/26 | | |
LORLAPULM, NCT05167500: Efficacy & Safety Study of Lorlatinib in ALK/ROS1 Metastatic NSCLC Patients With Compassionate Use Treatment |
|
|
| Completed | N/A | 118 | Europe | Lorlatinib, Lorviqua | Fundación GECP | Metastatic Non Small Cell Lung Cancer | 12/22 | 12/22 | | |
| Recruiting | N/A | 10000 | Europe | | Spanish Lung Cancer Group | Thoracic Tumors | 12/25 | 12/30 | | |
| Koppelman, Geread |
| Recruiting | 2/3 | 135 | Europe, RoW | Posaconazole 100 MG [Noxafil], gastro-resistant tablets Noxafil® 100 mg, Posaconazole 40 MG/ML, 105 ml Noxafil® 40 mg/ml oral suspension | Bambino Gesù Hospital and Research Institute, University of Exeter, Radboud University, Consorzio per Valutazioni Biologiche e Farmacologiche | Cystic Fibrosis, Aspergillosis | 04/23 | 11/23 | | |
| Muijs, Kristel |
| Recruiting | 3 | 396 | Europe | Photon Radiotherapy, Proton Radiotherapy, Proton Therapy | University of Aarhus, University of Leeds, KU Leuven, University College, London, Aarhus University Hospital, Technische Universität Dresden, Academisch Ziekenhuis Groningen, CNAO National Center of Oncological Hadrontherapy, Agenzia Nazionale per i Servizi Sanitari Regionali, Centre Antoine Lacassagne, Centre Leon Berard, Institut Curie, Maastro Clinic, The Netherlands, University College London Hospitals, The Christie NHS Foundation Trust, Paul Scherrer Institut, Center for Proton Therapy, HollandPTC, IBA worldwide, Varian- A Siemens Healthineer Company | Esophageal Cancer, Radiotherapy, Side Effect, Proton Therapy | 12/27 | 12/32 | | |
NCT03283527: Organoid Based Response Prediction in Esophageal Cancer |
|
|
| Recruiting | N/A | 100 | Europe | | University Medical Center Groningen | Organoid, Esophageal Cancer, Chemoradiation | 12/23 | 12/23 | | |
| Queck, Alexander |
CHANCE, NCT04613921: Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs |
|
|
| Recruiting | N/A | 3000 | Europe, Canada, Japan, US, RoW | Observational Protocol | European Foundation for Study of Chronic Liver Failure | Liver Diseases, Liver Cirrhosis, Acute-On-Chronic Liver Failure, Liver Transplant; Complications | 12/25 | 12/26 | | |
| Spikman, Joke |
MS-CEBA, NCT06016309: The Study: Determining Cognitive, Energetic, Behavioural and Affective (CEBA) Profiles in Multiple Sclerosis |
|
|
| Recruiting | N/A | 500 | Europe | There is no intervention. | University Medical Center Groningen, University of Groningen | Multiple Sclerosis | 07/27 | 07/27 | | |
| Reinhardt, Anniek |
MS-CEBA, NCT06016309: The Study: Determining Cognitive, Energetic, Behavioural and Affective (CEBA) Profiles in Multiple Sclerosis |
|
|
| Recruiting | N/A | 500 | Europe | There is no intervention. | University Medical Center Groningen, University of Groningen | Multiple Sclerosis | 07/27 | 07/27 | | |
| Yigit, Refika |
| Recruiting | 2 | 18 | Europe | Vvax001 therapeutic cancer vaccine | University Medical Center Groningen, Dutch Cancer Society, ViciniVax B.V | CIN3, Cervical Intraepithelial Neoplasia, Cervical Intraepithelial Neoplasia Grade 3, HPV 16 Infection | 02/24 | 04/24 | | |
| Eerkens, Anneke |
| Recruiting | 2 | 12 | Europe | Pembrolizumab Injection [Keytruda] | University Medical Center Groningen, Merck Sharp & Dohme LLC | Endometrial Cancer | 12/27 | 01/28 | | |
| Recruiting | 2 | 18 | Europe | Vvax001 therapeutic cancer vaccine | University Medical Center Groningen, Dutch Cancer Society, ViciniVax B.V | CIN3, Cervical Intraepithelial Neoplasia, Cervical Intraepithelial Neoplasia Grade 3, HPV 16 Infection | 02/24 | 04/24 | | |
| Recruiting | N/A | 40 | Europe | blood draws | University Medical Center Groningen | HNSCC, Head and Neck Cancer, Oropharynx Cancer, Hypopharynx Cancer, Larynx Cancer | 04/24 | 04/24 | | |
| Verhaar, Anne-Fleur |
CHASE, NCT06204237: Safety, Tolerability, and Biodistribution of [89Zr]Zr-DFO-APAC in Subjects With PAOD/CLI and Healthy Volunteers (Acronyms: 89Zr = Zirconium-89, DFO = Desferrioxamine, APAC = AntiPlatelet AntiCoagulant, PET/CT = Positron Emission Tomography/Computed Tomography) |
|
|
| Recruiting | 1 | 10 | Europe | [89Zr]Zr-DFO-APAC, PET/CT scan | Aplagon Oy, TRACER Europe BV | Peripheral Arterial Occlusive Disease, Critical Limb Ischemia | 06/25 | 06/25 | | |
| Recruiting | 1 | 32 | Europe | 89Zr-DFO-N-Suc-F8scFv, 89Zr-DFO-N-Suc-C9scFv, PET/CT scan | Var2 Pharmaceuticals, TRACER Europe BV | Solid Tumor, Colon Carcinoma, Rectal Carcinoma, Osteosarcoma, Chondrosarcoma, Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, Esophageal Carcinoma, Gastric Carcinoma, Pancreas Carcinoma, Bladder Carcinoma, Glioblastoma | 01/26 | 01/26 | | |
| Tan, Aaron |
| Recruiting | 1/2 | 470 | Europe, Canada, Japan, US, RoW | NVL-655 | Nuvalent Inc., Nuvalent, Inc. | Locally Advanced Solid Tumor, Metastatic Solid Tumor | 02/26 | 03/26 | | |
NCT05910827: Study of an Anti-HER3 Antibody, HMBD-001, With Docetaxel +/- Cetuximab in Advanced Squamous Non-small Cell Lung Cancers, and HMBD-001 + Cetuximab in Advanced Squamous Cell Cancers |
|
|
| Recruiting | 1/2 | 98 | RoW | HMBD-001, Docetaxel, Cetuximab | Hummingbird Bioscience, Merck KGaA, Darmstadt, Germany | Advanced or Metastatic Squamous Non-Small Cell Lung Cancer, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Esophageal Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Advanced Cutaneous Squamous Cell Carcinoma | 03/26 | 03/26 | | |
NCT06418412: A Pan-Asian Clinical Database of EGFR Exon 20 Insertion Mutated NSCLC |
|
|
| Recruiting | N/A | 600 | RoW | | National Cancer Centre, Singapore | Advanced EGFR Exon 20 Insertion Mutated Non-Small Cell Lung Cancer | 12/24 | 12/24 | | |
| Links, Mirthe |
| Recruiting | N/A | 25 | Europe | Low iodine diet | University Medical Center Groningen | Differentiated Thyroid Cancer | 03/26 | 08/26 | | |
| Not yet recruiting | N/A | 40 | Europe | Euthyrox (levothyroxine), Cytomel (liothyronine) | University Medical Center Groningen, Radboud University Medical Center | Differentiated Thyroid Cancer, Thyroid Cancer, Levothyroxine, Liothyronine, Thyroid Hormones | 05/26 | 08/26 | | |
